Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127342041 | 12734204 | 1 | I | 2015 | 20151112 | 20160912 | 20160912 | PER | US-GLENMARK PHARMACEUTICALS INC, USA.-2015GMK020809 | GLENMARK | 0.00 | Y | 0.00000 | 20160912 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127342041 | 12734204 | 1 | PS | GABAPENTIN. | GABAPENTIN | 1 | Oral | 4 DF, QID | 02151473 | 77662 | 4 | DF | TABLET | QID | |||||
| 127342041 | 12734204 | 2 | C | LOSARTAN. | LOSARTAN | 1 | Oral | UNK | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127342041 | 12734204 | 1 | Diabetic neuropathy |
| 127342041 | 12734204 | 2 | Hypertension |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127342041 | 12734204 | Dysgeusia | |
| 127342041 | 12734204 | Off label use | |
| 127342041 | 12734204 | Product odour abnormal |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |